Medcura Welcomes Gary P. Fischetti to Its Board of Directors
Medcura, Inc., a firm at the forefront of innovative hemostatic technologies, recently made headlines with the appointment of Gary P. Fischetti to its Board of Directors. Fischetti brings over 35 years of rich experience in the medical technology arena, having held significant leadership roles within global giants like Johnson & Johnson, particularly under its Ethicon and DePuy Synthes divisions.
The CEO of Medcura, Jim Buck, expressed enthusiasm about Fischetti's addition to the board, emphasizing that his expertise in innovation, regulatory strategies, and commercialization will prove crucial as the company progresses its flagship product, LifeGel™, through critical pre-clinical and human clinical trials. This particular hemostatic gel has already made a name for itself, recognized for its unique properties that resist swelling and is the first absorbable hemostatic agent to receive FDA Breakthrough Device designation.
Fischetti shared his eagerness to contribute to Medcura's vision. He highlighted the significant implications of LifeGel™, noting its potential to change standards in bleeding management during spinal surgeries. The gel is designed with features that could minimize bacterial growth and provide financial advantages for healthcare providers, ultimately reshaping the surgical hemostasis landscape.
In addition to his new role at Medcura, Fischetti holds the Chair position at Orchid Orthopedic Solutions and sits on the boards of Anika Therapeutics and Acuitive Technologies. His career at Johnson & Johnson spanned various countries and roles, culminating in leading North America’s medical devices sector overseeing all twelve businesses within that domain. Fischetti's illustrious background also saw him managing global operations for various companies under the DePuy Synthes umbrella, bringing a treasure trove of knowledge and experience to Medcura.
Medcura is on an ambitious path to innovate within the hemostatic products sector. Their proprietary biopolymer platform is designed to control bleeding quickly while promoting patient safety without burdensome preparation processes. With a diverse portfolio that includes gels, foams, powders, and more, Medcura serves surgical specialists, trauma care, and military medicine sectors. LifeGel™ stands out in this array, being the first absorbable hemostatic agent to achieve FDA's Breakthrough Device Designation, and has also garnered accolades such as the Best Technology in Spine Award by Orthopedics This Week.
It is important to note that while LifeGel™ is making strides, it remains investigational and its intended uses, indications, and claims have yet to receive FDA review or approval. Despite this, the breakthrough designation is a positive indication that LifeGel™ is viewed as a potentially transformative product in a field seeking innovation.
In summary, Gary P. Fischetti’s appointment to Medcura’s board not only reflects the company’s commitment to advancing its mission but also enhances its leadership team with an experienced figure capable of guiding it through future developments. Medcura and its stakeholders are eagerly anticipating the advancements in medical technology that this collaboration may yield, promising a substantial impact on how surgical hemostasis is approached in healthcare settings worldwide.
The CEO of Medcura, Jim Buck, expressed enthusiasm about Fischetti's addition to the board, emphasizing that his expertise in innovation, regulatory strategies, and commercialization will prove crucial as the company progresses its flagship product, LifeGel™, through critical pre-clinical and human clinical trials. This particular hemostatic gel has already made a name for itself, recognized for its unique properties that resist swelling and is the first absorbable hemostatic agent to receive FDA Breakthrough Device designation.
Fischetti shared his eagerness to contribute to Medcura's vision. He highlighted the significant implications of LifeGel™, noting its potential to change standards in bleeding management during spinal surgeries. The gel is designed with features that could minimize bacterial growth and provide financial advantages for healthcare providers, ultimately reshaping the surgical hemostasis landscape.
In addition to his new role at Medcura, Fischetti holds the Chair position at Orchid Orthopedic Solutions and sits on the boards of Anika Therapeutics and Acuitive Technologies. His career at Johnson & Johnson spanned various countries and roles, culminating in leading North America’s medical devices sector overseeing all twelve businesses within that domain. Fischetti's illustrious background also saw him managing global operations for various companies under the DePuy Synthes umbrella, bringing a treasure trove of knowledge and experience to Medcura.
Medcura is on an ambitious path to innovate within the hemostatic products sector. Their proprietary biopolymer platform is designed to control bleeding quickly while promoting patient safety without burdensome preparation processes. With a diverse portfolio that includes gels, foams, powders, and more, Medcura serves surgical specialists, trauma care, and military medicine sectors. LifeGel™ stands out in this array, being the first absorbable hemostatic agent to achieve FDA's Breakthrough Device Designation, and has also garnered accolades such as the Best Technology in Spine Award by Orthopedics This Week.
It is important to note that while LifeGel™ is making strides, it remains investigational and its intended uses, indications, and claims have yet to receive FDA review or approval. Despite this, the breakthrough designation is a positive indication that LifeGel™ is viewed as a potentially transformative product in a field seeking innovation.
In summary, Gary P. Fischetti’s appointment to Medcura’s board not only reflects the company’s commitment to advancing its mission but also enhances its leadership team with an experienced figure capable of guiding it through future developments. Medcura and its stakeholders are eagerly anticipating the advancements in medical technology that this collaboration may yield, promising a substantial impact on how surgical hemostasis is approached in healthcare settings worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.